American Association for Cancer Research
Browse

sorry, we can't preview this file

cd-20-0930_supps3.xlsx (27.14 kB)

Supplementary Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

Download (27.14 kB)
dataset
posted on 2023-04-04, 00:05 authored by Elisa Izquierdo, Diana M. Carvalho, Alan Mackay, Sara Temelso, Jessica K.R. Boult, Giulia Pericoli, Elisabet Fernandez, Molina Das, Valeria Molinari, Yura Grabovska, Rebecca F. Rogers, Maria Antonietta Ajmone-Cat, Paula Z. Proszek, Mark Stubbs, Sarita Depani, Patricia O'Hare, Lu Yu, Georgia Roumelioti, Jyoti S. Choudhary, Matthew Clarke, Amy R. Fairchild, Thomas S. Jacques, Richard G. Grundy, Lisa Howell, Susan Picton, Jenny Adamski, Shaun Wilson, Juliet C. Gray, Bassel Zebian, Lynley V. Marshall, Fernando Carceller, Jacques Grill, Maria Vinci, Simon P. Robinson, Michael Hubank, Darren Hargrave, Chris Jones
Supplementary Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

Funding

Children with Cancer UK Fellow

History

ARTICLE ABSTRACT

The survival of children with diffuse intrinsic pontine glioma (DIPG) remains dismal, with new treatments desperately needed. In a prospective biopsy-stratified clinical trial, we combined detailed molecular profiling and drug screening in newly established patient-derived models in vitro and in vivo. We identified in vitro sensitivity to MEK inhibitors in DIPGs harboring MAPK pathway alterations, but treatment of patient-derived xenograft models and a patient at relapse failed to elicit a significant response. We generated trametinib-resistant clones in a BRAFG469V model through continuous drug exposure and identified acquired mutations in MEK1/2 with sustained pathway upregulation. These cells showed hallmarks of mesenchymal transition and expression signatures overlapping with inherently trametinib-insensitive patient-derived cells, predicting sensitivity to dasatinib. Combined trametinib and dasatinib showed highly synergistic effects in vitro and on ex vivo brain slices. We highlight the MAPK pathway as a therapeutic target in DIPG and show the importance of parallel resistance modeling and combinatorial treatments for meaningful clinical translation. We report alterations in the MAPK pathway in DIPGs to confer initial sensitivity to targeted MEK inhibition. We further identify for the first time the mechanism of resistance to single-agent targeted therapy in these tumors and suggest a novel combinatorial treatment strategy to overcome it in the clinic.This article is highlighted in the In This Issue feature, p. 587

Usage metrics

    Cancer Discovery

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC